Related Experiment Video

Updated: Mar 20, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.7K

The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer

Hong Jun Kim1, Suk-Young Lee1, Sang Cheul Oh1

  • 1Division of Oncology/Hematology, Department of Internal Medicine, College of Medicine, Korea University Seoul, South Korea.

Frontiers in Physiology
|June 1, 2016
PubMed

Insights

New biologic agents targeting the inositide pathway show promise for advanced gastric and colorectal cancers. Research is ongoing to improve outcomes for patients with these difficult-to-treat malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Gastric and colorectal cancers are leading causes of cancer mortality with poor prognoses.
  • Combination chemotherapy with targeted and conventional agents is standard, but new treatments are needed.
  • Aberrant inositide signaling, driven by PTEN or PIK3CA mutations, is key in these cancers.

Purpose of the Study:

  • To review the inositide signaling pathway in gastric and colorectal cancers.
  • To discuss targeted agents inhibiting this pathway.
  • To summarize ongoing clinical trials for advanced/metastatic disease.

Main Methods:

  • Literature review of inositide signaling.
  • Analysis of targeted agents and their mechanisms.
  • Summary of clinical trial data for relevant agents.

Main Results:

  • The inositide pathway is a critical oncogenic driver in gastric and colorectal cancers.
  • Targeted agents inhibiting PI3K/AKT/mTOR are under investigation.
  • Clinical trials are evaluating these agents in advanced and metastatic settings.

Conclusions:

  • Targeting the inositide signaling pathway represents a promising therapeutic strategy.
  • Further research and clinical trials are essential to improve patient outcomes.
  • Combination therapies may enhance efficacy in advanced gastric and colorectal cancers.
Keywords:
AktPI3Kcolorectal cancergastric cancermTORphosphoinositidetargeted therapy

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K